Cepheid Q2 Revenues Climb 21 Percent, but Miss Analyst Estimates | GenomeWeb

NEW YORK (GenomeWeb News) – Cepheid's revenues grew 21 percent year over year during the second quarter, the Sunnyvale, Calif.-based firm reported after the close of the market on Thursday.

For the three months ended June 30, total revenues came in at $81.0 million, compared to $67.0 million a year ago. Wall Street analysts had expected revenues of $82.7 million.

Pacing revenue growth was reagent and disposable sales growth to $63.9 million from $49.5 million a year ago, a 29 percent increase. System sales increased 3 percent to $14.5 million from $14.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.